Lanreotide acetate
Modify Date: 2024-01-08 17:10:10
Lanreotide acetate structure
|
Common Name | Lanreotide acetate | ||
|---|---|---|---|---|
| CAS Number | 127984-74-1 | Molecular Weight | 1156.375 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C56H73N11O12S2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Warning | |
Use of Lanreotide acetateLanreotide is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) |
| Name | Somatuline |
|---|---|
| Synonym | More Synonyms |
| Molecular Formula | C56H73N11O12S2 |
|---|---|
| Molecular Weight | 1156.375 |
| Exact Mass | 1155.488159 |
| Appearance of Characters | white to off-white |
| Storage condition | ?20°C |
|
[Drug therapy for acromegaly].
Orv. Hetil. 154(39) , 1527-34, (2013) Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Desp... |
|
|
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.
Pituitary 16(3) , 354-62, (2013) Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeleta... |
|
|
Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013) We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and r... |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxo-2-butanyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)-D-alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:1) |
| 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-, (4R,7S,10S,13R,16S,19R)-, acetate (1:1) (salt) |
| Somatuline |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt) |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| Somatuline LP |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pe |
| lanreotide acetate |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt) |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6, |
| Somatuline LA |
| ntaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| Somatuline Autogel |
| 1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxypheny |
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Lanreotide acetate
- Price: ￥8398.0/100mg
- Purity: 97.0%
- Stocking Period: 1 Day
- Contact: Liu jia
- DC Chemicals Limited
- China
- Product Name: Somatuline
- Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Zhejiang Hangyu API Co., Ltd
- China
- Product Name: Lanreotide
- Price: $Inquiry/1kg
- Purity: 99.0%
- Stocking Period: 1 Day
- Contact: Vinnie
Get all suppliers and price by the below link: